Compare Delta Air Lines, Inc. (DAL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Zoetis Inc — how do they compare? Delta Air Lines, Inc. trades at $89.85 (market cap $59.46B), while Zoetis Inc trades at $73.06 (market cap $31.14B). The key difference: Delta Air Lines, Inc. is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| DAL | ZTS | |
|---|---|---|
Market Cap | $59.46B | $31.14B |
Sector | Industrials | Health |
52-Week High | $93.66 | $156.76 |
52-Week Low | $55.65 | $71.91 |
Enterprise Value | $74.77B | $38.70B |
Dividend Yield | 0.86% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $89.70, up 0.55% today, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $1.56 versus $1.49 expected, maintaining a consistent earnings beat streak. Revenue growth has accelerated from $50.6B in 2022 to $63.4B in 2025, while net income improved to $5.0B. Analyst consensus remains overwhelmingly positive with 82% buy ratings and a $108.27 price target representing 21% upside potential.
DAL presents compelling value with attractive valuation multiples (P/E 14.99, P/S 0.87) and strong profitability metrics (ROE 20.12%). Key risks include fuel cost volatility and competitive pressure, but the company's premium travel positioning and American Express partnership provide competitive advantages. The technical setup suggests continued upward momentum with support at $88-90 levels.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
